Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis

British Journal of Cancer

Volumn 82, Issue 11, 2000, Pages 1827-1834

  Costa Pereira, A P ^a   McKenna, S L ^b   Cotter, T G ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b NONE

Author keywords

Apoptosis; Camptothecin; Fas; Prostate cancer; SAPK JNK

Indexed keywords

ANDROGEN; ANISOMYCIN; ANTISENSE OLIGONUCLEOTIDE; CAMPTOTHECIN; CASPASE; FAS ANTIGEN; PHOSPHATASE; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE INDUCTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0034102894     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1149     Document Type: Article

References (48)

1. Bost F, McKay R, Dean N and Mercola D (1997) The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells. J Biol Chem 272: 33422-33429
2. Chang HY, Nishitoh H, Yang X, Ichijo H and Baltimore D (1998) Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daax. Science 281: 1860-1863
3. Costa-Pereira AP and Cotter TG (1999) Camptothecin sensitises androgen-indepedent prostate cancer cells to anti-Fas-induced apoptosis. Br J Cancer 80: 371-378
4. de Souza PL, Cooper MR, Imondi AR and Myers CE (1997) 9-Aminocamptothecin: a topoisomerase 1 inhibitor with preclinical activity in prostate cancer. Clin Cancer Res 3: 287-294
5. Dhanasekaran N and Reddy EP (1998) Signalling by dual specificity kinases. Oncogene 17: 1447-1455
6. Enari M, Talanian RV, Wong WW and Nagata S (1996) Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature (Lond) 380: 723-726
7. Finch A, Holland P, Cooper J, Saklatavata J and Kracht M (1997) Selective activation of JNK/SAPK by interleukin-1 in rabbit liver is mediated by MKK7. FEBS Lett 418: 144-148
8. Frost PJ, Belldegrun A and Bonavida B (1999) Sensitisation of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis. Prostate 41: 20-30
9. Furuya Y und Isaacs JT (1993) Differential gene regulation during programmed cell death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation. Endocrinology 133: 2660-2666
10. Goillot E, Raingeaud J, Ranger A, Tepper RI, Davis RJ, Harlow and Sanchez I (1997) Mitogen-activated protein kinase-mediated Fas apoptotic signalling pathway. Proc Natl Acad Sci USA 94: 3302-3307
11. Griffith TS, Brunner T, Fletcher SM, Green DR and Ferguson TA (1995) Fas-ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189-1192
12. Gupta S, Campbell D,. Derijard B and Davis R (1995) Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267: 389-393
13. Haldar S, Chintapalli J and Croce CM (1996) Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255
14. Ham J, Babij C, Whitfield J, Pfarr CM, Lallemand D, Yaniv M and Rubin LL (1995) A c-jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 14: 927-939
15. Hazzalin CA, Le Panse R, Cano E and Mahadevan LC (1998) Anisomycin selectively desensitises signalling components involved in stress kinase activation and fos and jun induction. Mol Cel Biol 18: 1844-1854
16. Hedlund TE, Duke RC, Schleicher MS and Miller GJ (1998) Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumour stage. Prostate 36: 92-101
17. Hsiang YH, Likan MG and Liu LF (1989) Arrest of replication forks by drug stabilised topoisomerase-1-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082
18. Juo P, Kuo CJ, Reynolds SE, Konz RF, Raingeaud J, Davis RJ, Biemann H-P and Blenis J (1997) Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases. Mol Cel Biol 17: 24-35
19. Juo P, Kuo CJ, Yuan J and Blenis J (1998) Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol 8: 1001-1008
20. Kastan MB, Onyyekwere O, Sidransky D, Vogeltein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
21. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S and Reed JC (1996) Immunohistochemical analysis of bcl-2, bax, hcl-X and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567-1576
22. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495
23. Kyriakis JM, Benerjee P, Nikolakaki E, Dai T, Rubic EA, Amhad MF, Avruch J and Woogett JR (1994) The stress-activated protein kinase subfamily of c-Jun kinases. Nature (Lond) 369: 156-160
24. Leibson PJ (1997) The Fas pathway in apoptosis. Adv Pharmacol 41: 107-132
25. Leppä S, Saffrich R, Ansorge W and Bohmann D (1998) Differential regulation of c-Jun by ERK and JNK during PC12 differentiation. EMBO J 17: 4404-4413
26. Lenczowski JM, Dominguez L, Eder AM, King LB, Zacharchuk CM and Ashwell JD (1997) Lack of a role for jun kinase and AP-1 in Fas-induced apoptosis. Mol Cel Biol 17: 170-181
27. Longthorne VL and Williams GT (1997) Caspase activity is required for commitment to Fas-mediated apoptosis. EMBO J 16: 3805-3812
28. Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, Wishnow K, Kaplan I, Stork PJS and Loda M (1997) Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest 76: 37-51
29. Magi-Galluzzi C, Montironi R, Yao H, Cangi MG, Wishnow K and Loda M (1998) Mitogen-activated protein kinases and apoptosis in PIN. Virchows Arch 432: 407-413
30. Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, Gillieron C, Boschert U, Vial-Kneeht, Martinou J-C and Arkinstall S (1997) Bcl-2 undergoes phosphorylation by the c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutivety active GTP-binding protein Rac 1 J Biol Chem 272: 25238-25242
31. Muhlenbeek F, Haas E, Schwenzer R, Schubert G, Grell M, Smith C, Scheurich P and Wajant H. TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways. J Biol Chem 273: 33091-33098
32. O'Connell I, O'Sullivan GC, Collins JK and Shanahan F (1996) The Fas counterattack: Fas-mediated cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075-1082
33. Oehm A, Berhmann I, Falk W, Pawlita M, Maier G, Klas G, Li-Weber CM, Richards S, Dhein J, Trauth BC, Ponsting H and Krammer PH (1992) Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumour necrosis factor/nerve growth factor receptor superfamily: sequence identity with the Fas antigen. J Biol Chem 267: 10709-10715
34. Park J, Kim I, Oh YJ, Lee K-W, Han P-L and Choi E-J (1997) Activation of c-Jun N-terminal kinase antagonises an anti-apoptotic action of Bcl-2. J Biol Chem 272: 16725-16728
35. Reed JC (1997) Bcl-2 family proteins: role in dysregulation of apoptosis and chemoresistance in cancer. In: Apoptosis and Cancer, Martin SJ (ed). Karger Landes Systems, Basel, Switzerland.
36. Rokhlin OW, Glover RA and Cohen MB (1998) Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7. Cancer Res 58: 5870-5875
37. Sánchez-Perez I, Murguía JR and Perona R (1998) Cisplatin induces a persistent activation of JNK thai is related to cell death. Oncogene 16: 533-540
38. Smeal T, Binetruy B. Mercola DA, Birrer M and Karin M (1991) Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature (Lond) 354: 494-496
39. Su GH, Hilgers W, Shekher MC, Tang DJ, Yeo CJ, Hruban RH and Kern SE. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumour suppressor gene. Centrer Res 58: 2339-2342
40. Teng DH, Perry WL, Hogan JK, Baumgard M, Bell R, Berry S, Davis T, Frank D, Frye C, Hattier T, Hu R, Jammulapati S, Janecki T, Leavitt A, Mitchell JT, Pero R, Sexton D, Schroeder M, Su PH, Swedlund B, Kyriakis JM, Avruch J, Bartel P. Wong AK, Oliphant A, Thomas A, Skolnick MH and Tuvtigan SV (1997) Human mitogen-activated protein kinase kinase 4 as a candidate tumour suppressor. Cancer Res 57: 4177-4182
41. Toyashima F, Moriguchi T and Nishida E (1997) Fas induces cytoplasmic apoptotic responses and activation of the MKK7-JNK/SAPK and MKK6-p38 pathways independent of CPP32-like proteases. J Cell Biol 139: 1005-1015
42. Uslu R, Borsellino N, Frost P, Gában H, Ng C-P, Mizutani Y, Belldegrun A and Bonavida B (1997) Chemosensitization of human prostate carcinoma cell lines to anti-Fas mediated cytotoxicity and apoptosis. Clin Cancer Res 3: 963-972
43. Villunger A, Egle A, Marschitz I, Kos M, Böck G, Ludwig H, Geley S, Kofler R and Greil R (1997) Constitutive expression of Fas (APO-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumour induced suppression of immune surveillance. Blood 90: 12-20
44. Wyllie AH, Kerr JFR and Currie AR (1980) Cell death: the significance of apoptosis. Int Rev Cytol 68: 251-306
45. Xu S and Cobb MH (1997) MEKK1 binds directly to the c-Jun N-terminal kinases/strcss-activated protein kinases. J Biol Chem 272: 32056-32060
46. Yamamoto K, Ichijo H and Korsmeyer SJ (1999) BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-Terminal protein kinase pathway normally actuated at G2/M. Mot Cel Biol 19: 8469-8478
47. Yonehara S, Ishi A and Yonehara M (1989). A cell-killing monoclonal antibody (anti-Fas) to a surface antigen co-downregulated with the receptor of tumour necrosis factor. J Exp Med 169: 1747-1756
48. Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM and Rinker-Schaeffer CW (1999) Mitogen-activated protein kinase kinase 4/Stress-activated protein/Erk kinase 1 (MKK4/SEK1) a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Rev 59: 5483-5487